In combination with FEC/TE, I2 treatment exhibited a synergic effect on cancer cell apoptosis and impaired expression of chemoresistance markers (BIRC5 and HIF1A) as well as changes in the expression of specific EMT markers (increased E-cad expression and decreased Vimentin expression). This evidence concerns the gene CDH1 and cancer.